Dr Ohrstrom was previously part of the senior management team that took ZymoGenetics public, and played a key role in bringing recombinant human thrombin to the US market. Dr Ohrstrom will be based in Seattle, Washington, where ProFibrix has established a wholly owned subsidiary.
According to ProFibrix, its subsidiary ProFibrix Inc will facilitate the preparations of a global pivotal Phase II/III trial for the lead product Fibrocaps, to be conducted in 2009/2010. Additionally, it is expected to expand the company’s reach to additional drug development expertise and at the same time provide easy access to US investors for the follow-up financing of ProFibrix.
Jaap Koopman, founder and CEO of ProFibrix, said: “We are delighted with the decision of Dr Ohrstrom to join ProFibrix. His extensive expertise in the management of drug development and business operations will be a tremendous asset to ProFibrix as we continue to move our products through clinical development towards commercialization and prepare for the next financing round early next year.”